UB-312 is under clinical development by Vaxxinity and currently in the Phase I in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.
According to GlobalData, the latest event to affect UB-312’s likelihood of approval (LoA) and phase transition for Lewy Body Dementia took place on 25 Aug 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway.
GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their UB-312 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.
UB-312 is under development for the treatment of Parkinson's disease and multiple system atrophy (MSA) and for dementia with lewy bodies. The vaccine candidate is an endobody, it acts by targeting alpha-synuclein protein. It is developed based on synthetic peptide vaccine technology.
Vaxxinity is a biotechnology company that enables the innovation of synthetic peptide vaccines to prevent or treat infectious diseases. It offers an innovative platform that has the power to activate different arms of the immune system selectively and to neutralize targets with high specificity. The company is headquartered in Dallas, Texas, the US.
Quick View UB-312 LOA Data
|Highest Development Stage|